Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Oscar Lambret
Ferring Pharmaceuticals
Ocellaris Pharma, Inc.
NRG Oncology
Astellas Pharma Inc
Dana-Farber Cancer Institute
Actym Therapeutics, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Day One Biopharmaceuticals, Inc.
Medical Diagnostic Laboratories, LLC
Bristol-Myers Squibb
G1 Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Mayo Clinic
University of Chicago
Elevation Oncology
Ohio State University Comprehensive Cancer Center
Seagen Inc.
Sotio Biotech Inc.
SWOG Cancer Research Network
Shanghai PerHum Therapeutics Co., Ltd.
Istari Oncology, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Taris Biomedical LLC
Altor BioScience
Duke University
ADC Therapeutics S.A.
UroGen Pharma Ltd.
Pfizer
Sumitomo Pharma America, Inc.
Cedars-Sinai Medical Center
Pfizer
Pfizer
The University of Texas Health Science Center at San Antonio
University of Texas Southwestern Medical Center
Fusion Pharmaceuticals Inc.
SCRI Development Innovations, LLC
Hoosier Cancer Research Network
pharmaand GmbH
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Genmab
Pfizer
pharmaand GmbH
Bristol-Myers Squibb
4D pharma plc
Bristol-Myers Squibb
xCures